Summary
EIDP, Inc. (CTA-PB) filed an 8-K on August 24, 2017, detailing an amendment to a Separation Agreement between E. I. du Pont de Nemours and Company (“DuPont”) and The Chemours Company (“Chemours”). This amendment, effective August 24, 2017, addresses significant aspects of DuPont's previously announced settlement of litigation concerning perfluorooctanoic acid (PFOA) exposure. It specifically outlines the cost-sharing arrangements between DuPont and Chemours related to this settlement and potential future PFOA-related costs. The core financial impact for DuPont is the scheduled payment of $320.35 million to plaintiffs in the MDL litigation on September 1, 2017. This payment fulfills DuPont's liability under the settlement and its obligations as per the amended Separation Agreement. Investors should note that this filing primarily pertains to the financial and legal ramifications of the PFOA litigation settlement between DuPont and Chemours, with EIDP, Inc. (CTA-PB) acting as the reporting entity for this specific event.
Key Highlights
- 1EIDP, Inc. (CTA-PB) reported an amendment to the Separation Agreement between DuPont and Chemours on August 24, 2017.
- 2The amendment addresses DuPont's settlement of PFOA-related personal injury litigation.
- 3It outlines the cost-sharing arrangements between DuPont and Chemours for this settlement.
- 4The agreement also covers potential future PFOA-related costs.
- 5DuPont is set to pay $320.35 million on September 1, 2017, to satisfy its settlement obligations.
- 6This filing serves to implement previously announced agreements concerning the PFOA litigation.